Literature DB >> 717642

Reversal reactions in lepromatous leprosy following transfer factor therapy.

R C Hastings, C K Job.   

Abstract

Five patients with active leprosy, four with polar lepromatous (LL) and one with borderline lepromatous (BL) disease, were each treated with transfer factor (TF) from approximately 7.4 x 10(9) lymphocytes given in 36 divided doses over a 12-week period. The TF was prepared from blood donated by normal, healthy, lepromin skin test-positive individuals. During treatment all four of the LL patients, but not the BL patient, developed clinical reversal reactions. Histopathologically, skin biopsies in these four LL patients showed evidence of transformation of collections of multibacillary macrophages into paucibacillary epithelioid cells and giant cells. To our knowledge, this is the first histopahtologic documentation of reversal reactions occurring in polar LL. To the extent that reversal reactions are evidence of effective cell-mediated immunity of Mycobacterium leprae, these results indicate that TF is capable of at least partial correction of the immunologic deficit of lepromatous leprosy.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 717642     DOI: 10.4269/ajtmh.1978.27.995

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  3 in total

1.  Induction and treatment of anergy in murine leprosy.

Authors:  Mario Juarez-Ortega; Víctor G Hernandez; Patricia Arce-Paredes; Enrique B Villanueva; Miguel Aguilar-Santelises; Oscar Rojas-Espinosa
Journal:  Int J Exp Pathol       Date:  2014-12-21       Impact factor: 1.925

2.  Leprosy therapy, past and present: can we hope to eliminate it?

Authors:  P V S Prasad; P K Kaviarasan
Journal:  Indian J Dermatol       Date:  2010-10       Impact factor: 1.494

3.  Widespread intradermal accumulation of mononuclear leukocytes in lepromatous leprosy patients treated systemically with recombinant interferon gamma.

Authors:  C Nathan; K Squires; W Griffo; W Levis; M Varghese; C K Job; A R Nusrat; S Sherwin; S Rappoport; E Sanchez
Journal:  J Exp Med       Date:  1990-11-01       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.